Company Profile

Grindeks is the Baltic leader pharmaceutical group. Net sales break down by activity as follows: - research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.; - production of pharmaceutical active ingredients (5.1%). Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).

Employees

1,505

Sector

Pharmaceuticals

More about the company

24-04-03	Grindeks Opens New Subsidiaries Worldwide	CI
21-02-24	JSC Grindeks Appoints Andrejs Liberts as the Member of the Board	CI
21-01-21	SIA Liplat Holding completed the acquisition of additional 2.6% stake in Akciju sabiedriba Grindeks for €3.4 million.	CI
20-12-21	SIA Liplat Holding made an offer to acquire the remaining 5.84% stake in Akciju sabiedriba Grindeks for €7.6 million.	CI
20-11-26	Akciju Sabiedriba Grindeks Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
20-08-27	Akciju Sabiedriba Grindeks Reports Earnings Results for the Second Quarter Ended June 30, 2020	CI
20-08-18	Akciju sabiedriba Grindeks Approves to Pay Dividend, Payable on September 17, 2020	CI
20-08-04	Akciju sabiedriba Grindeks Proposes to Pay Dividend, Payable on September 17, 2020 and November 17, 2020, Respectively	CI
20-03-05	Grindeks Completes Phase 1 Clinical Study of its New Investigational Medicinal Product Methyl-GBB	CI
20-02-28	As Grindeks Reports Earnings Results for the Full Year Ended December 31, 2019	CI
20-02-04	JSC Grindeks Announces Appointment of Juris Hmelnickis as the Chairman of the Board	CI
20-01-22	JSC Grindeks Announces Resignation of Juris Bundulis as Chairman of the Board	CI
19-12-19	JSC Grindeks Receives A Certificate of Saudi Food and Drug Authority	CI

21-03-03	Grindeks : In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit	AQ
21-02-24	Grindeks : Andrejs Liberts appointed as the member of the board of JSC “Grindeks”	AQ
21-02-12	Grindeks : Delisting of AS „Grindeks” shares from the Baltic Main list	AQ
21-02-09	Grindeks : On exclusion of shares from the regulated market	AQ
21-01-26	Grindeks : Information about refusal to repurchase the final shares of JSC “Grindeks”	AQ

Manager	Title	Age	Since
Janis Romanovskis CEO	Chief Executive Officer	66	2010-04-21
Andrejs Liberts PRN	Corporate Officer/Principal	41	2021-02-23
Iveta Zomerfelde SAM	Sales & Marketing	-	2015-03-02

Director	Title	Age	Since
Kirovs Lipmans CHM	Chairman	85	2002-12-31
Anna Lipmane BRD	Director/Board Member	78	2007-12-31
Filips Lipmans BRD	Director/Board Member	48	2003-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GRINDEKS	+9.69%	-14.00%	-	-	125M
ELI LILLY AND COMPANY	+0.45%	+3.01%	+54.61%	+124.91%	1,135B
JOHNSON & JOHNSON	+0.69%	+4.68%	+39.61%	+78.31%	635B
ABBVIE INC.	-0.07%	+1.02%	+25.23%	+96.67%	505B
ROCHE HOLDING AG	+1.43%	+4.31%	+48.28%	+67.12%	378B
MERCK & CO., INC.	-3.14%	-2.05%	+59.86%	+33.28%	358B
NOVARTIS AG	-0.41%	+2.64%	+23.58%	+49.82%	295B
ASTRAZENECA PLC	+0.23%	+3.66%	+2.45%	+23.69%	266B
AMGEN INC.	+0.51%	+3.89%	+51.62%	+63.68%	237B
GILEAD SCIENCES, INC.	+1.05%	+2.94%	+30.79%	+100.72%	193B
Average	+1.04%	+1.60%	+37.34%	+70.91%	444.85B
Weighted average by Cap.	+0.13%	+1.63%	+41.32%	+83.24%

Grindeks Stock

Stocks

GRD1R

LV0000100659

Pharmaceuticals

Latest news: Grindeks

Press Releases: Grindeks

Quotes and Performance

Managers and Directors: Grindeks

Generic Pharmaceuticals

Company Profile